ImmunityBio Stock Crashes 21% Following FDA Warning on Cancer Therapy

ImmunityBio, Inc. found itself at the center of a securities fraud class action lawsuit following a significant regulatory setback that sent its stock price into freefall. On March 24, 2026, the Food and Drug Administration (FDA) issued a formal warning letter to the company regarding misleading advertisements for its cancer immunotherapy candidate Anktiva, triggering an immediate and severe market reaction. The disclosure of the FDA warning resulted in the company's stock plummeting 21% to $7.42 per share, a dramatic decline that wiped out substantial shareholder value and prompted legal action from affected investors.

The lawsuit has opened a class action period for investors who purchased ImmunityBio shares during a specific window, with implications for the company's credibility, pipeline strategy, and near-term financial outlook. For shareholders, this development raises critical questions about corporate disclosure practices, regulatory compliance, and the viability of the company's clinical and commercial ambitions in the competitive oncology therapeutics market.

The Regulatory Trigger and Market Impact

The FDA warning letter represents a significant regulatory challenge for ImmunityBio, signaling that the agency determined the company engaged in misleading promotional practices regarding Anktiva, its investigational cancer therapy. Warning letters from the FDA are serious enforcement actions that indicate the agency believes a company has violated federal law regarding drug advertising and promotion—a critical issue in the pharmaceutical industry where marketing claims must be supported by substantial evidence.

The market's response was swift and unforgiving:

• Stock decline: 21% drop following the warning letter disclosure
• Share price: Fell to $7.42 per share on the news
• Timeline: FDA warning issued March 24, 2026
• Class action eligibility window: Shares purchased between January 19, 2026 and March 24, 2026
• Lead plaintiff application deadline: May 26, 2026

The significant gap between the alleged start of the fraudulent conduct (January 19, 2026) and the FDA warning (March 24, 2026) suggests investors were exposed to misleading information for approximately two months before the market correction occurred. This extended period of alleged misrepresentation is a key factor in class action claims, as it demonstrates that shareholders operated with incomplete or inaccurate information about the company's regulatory standing and product prospects.

Market Context: Cancer Immunotherapy Landscape and Competitive Pressures

ImmunityBio operates in the highly competitive oncology immunotherapy sector, where regulatory approvals, clinical efficacy data, and promotional compliance are paramount. The company's focus on cancer treatments positions it against established players like Merck ($MRK), Bristol Myers Squibb ($BMY), and Regeneron ($REGN), as well as numerous emerging biotech firms pursuing similar approaches.

The FDA warning letter must be understood within the broader context of pharmaceutical marketing oversight. The agency has intensified its scrutiny of promotional claims in recent years, particularly for drugs still in clinical development that have not yet received full marketing approval. For investigational therapies like Anktiva, promotional materials must strictly adhere to FDA guidance and cannot overstate efficacy, understate risks, or make claims that exceed the current state of clinical evidence.

Key industry considerations include:

• Regulatory environment: The FDA has shown increased willingness to issue warning letters and enforcement actions for promotional violations
• Clinical data requirements: Cancer immunotherapy claims require rigorous clinical evidence and transparent communication about trial endpoints
• Market competition: The oncology space is crowded, making regulatory compliance and clinical differentiation critical competitive advantages
• Investor sensitivity: Biotech investors are acutely attuned to regulatory setbacks, particularly those involving marketing practices that could delay or derail approvals

The timing of the warning letter also raises questions about ImmunityBio's disclosure controls and internal compliance procedures. Companies are expected to have robust systems to ensure marketing materials meet regulatory standards before dissemination.

Investor Implications and Securities Law Considerations

The class action lawsuit against ImmunityBio reflects a critical principle in securities law: companies must make timely and accurate disclosures about material information that could affect investor decision-making. The allegation here is that ImmunityBio engaged in misleading promotional practices for Anktiva without adequately disclosing regulatory risks to shareholders—a failure that allowed the stock to trade at potentially inflated levels before the FDA warning became public.

For investors who purchased shares during the January 19 to March 24, 2026 period, the 21% stock decline represents direct economic harm. The lawsuit seeks to recover damages for shareholders who can demonstrate they purchased shares during this window and suffered losses when the true regulatory status became known.

The broader implications for shareholders include:

• Pipeline risk: The FDA warning raises questions about whether Anktiva faces approval delays or whether claims about its efficacy were overstated
• Management credibility: Regulatory enforcement actions can damage confidence in a company's leadership and compliance culture
• Capital availability: Biotech companies heavily dependent on investor funding may face higher capital costs following regulatory setbacks
• Clinical viability: The warning letter may indicate underlying issues with trial design, efficacy data, or comparative claims that could impact Anktiva's ultimate market prospects

The lead plaintiff application deadline of May 26, 2026 establishes a critical window for investors to formally notify the court of their intent to serve as representatives in the case. Lead plaintiffs often play important roles in settlement negotiations and ensuring that class members receive appropriate compensation.

Forward Outlook and Resolution Pathways

The path forward for ImmunityBio involves several potential scenarios. The company must respond to the FDA warning letter with a plan to correct the violations, which could include revising promotional materials, implementing enhanced compliance procedures, or providing the agency with additional clinical evidence to support marketing claims. The company's response will be closely watched by both regulators and investors.

Simultaneously, the securities litigation will proceed through discovery, where both sides will examine company communications, internal discussions about Anktiva's efficacy, and the decision-making process around promotional materials. Settlement discussions often accompany these cases, with outcomes typically involving compensation funded through company insurance or direct payments to the class.

For investors holding ImmunityBio shares, the regulatory and legal developments create significant near-term uncertainty. The company's ability to resolve the FDA concerns, maintain momentum in its clinical programs, and restore investor confidence will be critical factors determining whether the stock recovers from its current depressed levels or faces further decline.

The ImmunityBio situation serves as a cautionary tale about the importance of regulatory compliance and accurate disclosure in the biotech sector, where single regulatory actions can dramatically alter shareholder value. As the May 26, 2026 deadline approaches for lead plaintiff applications, affected investors face a concrete opportunity to participate in recovery efforts, while the broader market watches to see whether ImmunityBio can salvage its regulatory relationships and clinical ambitions.